Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Pullin-GS who wrote (7212)	4/7/1998 12:06:00 AM
From: AlienTech	Read Replies (2) \| Respond to of 120523

Here take some of this and it will fix all your problems... Zantac - Anti ulcer is the #1 drug.. man a lot of stressed up people out there.. Prozac # 2 - A lot of fucked up people out there Zoloft # 4 - Dont feel like jumping off buildings then try this one instead. Prilosec replaces Zantac as 1997 top seller Tuesday, March 31, 1998 09:24 PM By Susan Spielberg NEW YORK, March 31 (Reuters) - Prilosec, Merck Astra Inc's anti-ulcer drug, became the number one selling prescription drug in the U.S. in 1997, while Zantac, last year's winner, slipped to sixth place. Sales of Prilosec, marketed by a joint venture between Sweden's Astra Ab (Stockholm:ASTRa) and Merck & Co Inc (Nyse:MRK) , rose 31.0 percent in 1997 from 1996 levels, to $2.3 billion, according to IMS America Ltd, a health care and pharmaceutical information company. IMS collects its prescription data from drug stores, hospitals, clinics, long term care facilities and HMOs. Zantac, Glaxo Wellcome Plc's (Lse:GLXO) anti-ulcer drug, went off patent last July and sales fell 37.7 percent to $1.1 billion in 1997. A generic version of Zantac is now made by Novopharm Ltd of Canada. Eli Lilly and Co's (Nyse:LLY) antidepressant, Prozac, marched to second place from third, with 1997 sales of $1.9 billion, up 12.2 percent from the year before. Zocor, Merck's cholesterol-lowering drug, leapfrogged to third place with sales of $1.4 billion, up 35.9 percent from last year. Zocor was in sixth place last year, behind Epogen and Zoloft, which remain in fourth and fifth places, respectively. Epogen, a booster of red blood cell count made by Amgen Inc (Nasdaq:AMGN) , had sales of $1.2 billion in 1997, up 0.9 percent. Sales of Zoloft, Pfizer Inc's (Nyse:PFE) antidepressant, rose 8.9 percent to $1.2 billion. A table of the top 10 prescription drugs follows: Rank Drug $ Sales (Mil.) Pct. Change 0 Viagra 6,000.0 +99.9 1 Prilosec 2,281.8 +31.0 2 Prozac 1,942.0 +12.2 3 Zocor 1,379.3 +35.0 4 Epogen 1,200.8 + 0.9 5 Zoloft 1,195.9 + 8.9 6 Zantac 1,097.2 -37.7 7 Paxil 949.3 +36.4 8 Norvasc 914.8 +26.5 9 Claritin 907.7 +38.1 10 Vasotec 843.4 - 2.6